The therapeutic effect of allopurinol in fatty liver disease in rats

Basit Öğe Kaydı
dc.authorscopusid23974366400
dc.authorscopusid55534662900
dc.authorscopusid57217131182
dc.authorscopusid58728199000
dc.authorscopusid8633854300
dc.authorscopusid8955041400
dc.authorscopusid55469991100
dc.contributor.authorBarişik, V.
dc.contributor.authorKorkmaz, H.A.
dc.contributor.authorÇekdemir, Y.E.
dc.contributor.authorTorlak, D.
dc.contributor.authorAktuğ, H.
dc.contributor.authorYavaşoğlu, A.
dc.contributor.authorErbaş, O.
dc.date.accessioned2024-08-25T18:47:51Z
dc.date.available2024-08-25T18:47:51Z
dc.date.issued2023
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground. Hyperuricemia is associated with non-alcoholic fatty liver disease (NAFLD). Aim. We therefore aimed at evaluating the influence of allopurinol on the course of NAFLD in rats. Study Design. We divided 21 mature albino Sprague Dawley rats into three groups: Controls (n = 7, normal diet for 12 weeks); NAFLD rat models (by feeding water containing 30% fructose for first 8 weeks) treated with allopurinol subsequently for the next 4 weeks (n = 7); and similar case treated with placebo (saline) subsequently for the next 4 weeks (n = 7). Methods. We compared the histopathological scores, IL-1 and IL-2 immunoexpression levels across the groups. Liver histopathological score was determined by observing the steatosis (the percentage of liver cells containing fat): <25% = 1+, 25% - 50% = 2+, 51% - 75% = 3+, >75% = 4+; inflammation and necrosis: 1 focus per low-power field = 1+; and 2 or more foci = 2+. The number of liver IL-1 and IL-2 positive cells was measured by systematically scoring at least 100 hepatocyte cells per field in 10 fields of tissue sections by a magnification of 100. Results. Xanthine oxidase (XO) activity and lipid peroxidation was significantly different in the allopurinol group compared to the saline group (XO; 0.098 ± 0.006 mU/mg vs. 0.162 ± 0.008 mU/mg, p = 0.01, 0.116 ± 0.040 nmol malondialdehyde/mg versus 0.246 ± 0.040 nmol malondialdehyde /mg, p = 0.01). The allopurinol group had lower histopathological scores, IL-1 and IL-2 immunoexpression levels in the liver compared to the saline group (2.13 ± 0.35 against 5.45 ± 0.24, p = 0.003, IL-1; 5.76 ± 0.43 against 12.85 ± 3.26, p = 0.023, IL-2; 8.55 ± 1.14 against 56.23 ± 7.12, p = 0.002). Conclusions. Allopurinol has a therapeutic role against the progression of NAFLD of the rats. © 2023, Acta Endocrinologica Foundation. All rights reserved.en_US
dc.identifier.doi10.4183/aeb.2023.155
dc.identifier.endpage162en_US
dc.identifier.issn1841-0987
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-85180256525en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage155en_US
dc.identifier.urihttps://doi.org/10.4183/aeb.2023.155
dc.identifier.urihttps://hdl.handle.net/11454/102066
dc.identifier.volume19en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherActa Endocrinologica Foundationen_US
dc.relation.ispartofActa Endocrinologicaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240825_Gen_US
dc.subjectAllopurinolen_US
dc.subjectHyperuricemiaen_US
dc.subjectNonalcoholic fatty liver diseaseen_US
dc.subjectalanine aminotransferaseen_US
dc.subjectallopurinolen_US
dc.subjectaspartate aminotransferaseen_US
dc.subjectfructoseen_US
dc.subjectimmunoglobulin enhancer binding proteinen_US
dc.subjectinterleukin 1en_US
dc.subjectinterleukin 2en_US
dc.subjectlow density lipoprotein cholesterolen_US
dc.subjectmalonaldehydeen_US
dc.subjecttriacylglycerolen_US
dc.subjecturic aciden_US
dc.subjectxanthine oxidaseen_US
dc.subjectanimal experimenten_US
dc.subjectanimal modelen_US
dc.subjectanimal tissueen_US
dc.subjectArticleen_US
dc.subjectbody weighten_US
dc.subjectcholesterol blood levelen_US
dc.subjectcontrolled studyen_US
dc.subjectechographyen_US
dc.subjectfatty liveren_US
dc.subjectglucose blood levelen_US
dc.subjecthistopathologyen_US
dc.subjectinflammationen_US
dc.subjectlipid peroxidationen_US
dc.subjectliver cellen_US
dc.subjectmaleen_US
dc.subjectnonhumanen_US
dc.subjectraten_US
dc.subjectsteatosisen_US
dc.subjecttherapy effecten_US
dc.titleThe therapeutic effect of allopurinol in fatty liver disease in ratsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu